




A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen

Hoosier Oncology Group GU12-160

Current state of post-platinum BC treatment

Overall Survival: Intent to Treat Population (N= 370)




* Stratified log rank test


Agent	RR	PFS	OS
Docetaxel	13	4	9
Paclitaxel	10	2	7
Vinflunine	9	3	7
Gemcitabine	17	4	8
Pemetrexed	23	3	10

Study Background

This study will evaluate the potential clinical benefit of OGX-427, a second generation antisense oligonucleotide (ASO), that inhibits heat shock protein 27 (Hsp27) production



Hsp27: A Stress-activated Cytoprotective Protein that Mediates Treatment Resistance in Most Cancers



Treatment with OGX-427 in Human Bladder Cancer Cells






Fig. x1: Crystal violet staining and OD 560 nM reading 24 hours after two transfection using oligofectamine. Media changed each transfection day after 6 hours of incubation with OPTIMEM and ASO in increasing concentrations.

Borealis-2 (HOG 12-160) Study Schema



Key eligibility Criteria

- 1) Post-platinum metastatic UC
- 2) Cr < 1.5 x ULN
- 3) ECOG PS 0-1
- 4) No prior docetaxel

Correlative Investigations

- 1) Serum HSP27
- 2) CTC's
- 3) Tumor and germline DNA

Borealis-2 (HOG 12-160) Study

- Number of Patients: 200
- Number of Sites: 27 US Sites
- Enrollment Period: 31 months
- First Site Activated: June 27, 2013
- Current Enrollment: 22 Patients